Navigation Links
SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
Date:1/8/2008

Organization expands SRA footprint in human health services around the

world

FAIRFAX, Va., Jan. 8 /PRNewswire-FirstCall/ -- As part of its overall expansion in new markets, SRA International, Inc. (NYSE: SRX) today announced the appointment of Timothy J. Atkin as Senior Vice President and Mike Toner as Vice President and Chief Financial Officer (CFO) of its new Global Health Sector (GHS) organization. GHS was formed in October 2007 to expand SRA's footprint in the health services marketplace following its acquisition of Constella Group, LLC, a global professional health services company.

"Global Health is an important business area for SRA . and one with great potential for growth," said SRA President & CEO Stanton Sloane.

SRA's GHS serves public, private, and non-profit clients in more than 40 countries around the world, including the U.S. Department of Health and Human Services (HHS) and the Department of Veterans Affairs (VA); both U.S. and United Kingdom international development agencies; Department of Defense (DoD) health, pharmaceutical, and biotechnology companies; and such foundations as the Bill & Melinda Gates Foundation.

Atkin, previously SRA Senior Vice President, Civil Sector, is responsible for the day-to-day management and operations of the GHS organization, overseeing the execution of all programs and the growth and expansion of the unit. In his previous role, Atkin was responsible for developing and managing all of SRA's civil government business, which included serving such clients as HHS, the Department of the Interior, the Department of Labor, Veterans Affairs, the Environmental Protection Agency (EPA), and the U.S. Agency for International Development (US
'/>"/>

SOURCE SRA International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
4. Department of Health & Human Services Names Dr. Eric Rose to National Biodefense Science Board
5. WellGen, Inc. Names Nancy E. Rawson, Ph.D., Chief Scientific Officer
6. Genome Technology Magazine Names Top Young Investigators of 2007
7. STEM CELLS Journal Names Co-Editors
8. Phlo Affiliate Names Director Of Marketing
9. Immunosyn Corporation Names G. David Criner as CFO
10. Navitas Names Dr. Dean Gesme as Medical Director
11. MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... world-leading provider of scientific, technical and medical information products ... study in Reproductive BioMedicine Online ... an abnormal chromosomal composition can be identified by the ... classifying the risk of genetic abnormality without a biopsy. ... a retrospective study, using their predictive model to assess ...
(Date:5/17/2013)... RESEARCH TRIANGLE PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability , ... drought and insect pressures , Syngenta ... grand opening celebration today at the company’s RTP Innovation ... Crop Lab allows company researchers to simulate any agricultural ...
(Date:5/17/2013)... 2013  Cellular Biomedicine Group (OTCQB: CBMG) today ... the total projected enrollment required for its Phase ... efficacy of the medical technology haMPC (Human Adipose-derived ... To date the trial has had no Severe ... I open label clinical research trial for KOA, ...
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce ... Switzerland -based Kenta Biotech to acquire ... (mAb) products, and technologies. This asset portfolio purchase ... of infections by common pathogens including drug resistant ... Pseudomonas aeruginosa , Acinetobacter baumannii and ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... Jan. 12 Synvista Therapeutics, Inc. (NYSE Alternext ... its BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial ... measure the effect of alagebrium on exercise tolerance in patients ... completing enrollment of its BREAK ( B eginning a ...
... Ill. and SANTA ANA, Calif., Jan. 12 ,Abbott ( NYSE: ... EYE ) announced,today a definitive agreement for Abbott to acquire ... value of approximately $2.8 billion, inclusive,of estimated net debt at ... AMO,is a global leader in ophthalmic care, comprised of three ...
... Bavarian Nordic,owns several United States patents relating ... MVA-BN(R), which is the basis for its smallpox,vaccine, ... for delivering,recombinant vaccines. Bavarian Nordic has asserted three ... The claim in this case is that Oxford,BioMedica ...
Cached Biology Technology:Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 2Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7Bavarian Nordic's Case Against Oxford BioMedica 2
(Date:5/17/2013)... 2013) The AGA Research Foundation announced a new ... between the gut microbiota, one of today,s most exciting ... , The AGA Research Awards Panel selected Andrew T. ... Hospital and Harvard Medical School, Boston, as the 2013 ... will receive $25,000 of funding, commencing in July 2013, ...
(Date:5/17/2013)... May 17, 2013, Shenzhen, China---- Why Tibetan antelope ... Qinghai-Tibetan Plateau? In a collaborative research published in ... BGI, and other institutes provide evidence that some ... adaption to harsh highland environments. The data in ... specific genetic mechanisms and the biology of other ...
(Date:5/16/2013)... Bethesda, MD (May 17, 2013) Illustrating a ... the American Gastroenterological Association (AGA) Research Foundation ... Future Student Research Fellowship Award recipients. Supported by ... Kidney Diseases (NIDDK), this new award helps underrepresented ... digestive disease and nutrition research. , "By establishing ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... found a group of mutations involved in T-cell acute ... in clinical use to treat other diseases, can eliminate ... next week in Nature Genetics and may ... The study was led by researcher Joo T. ...
... that predisposes people to acute myeloid leukemia and myelodysplasia ... the GATA2 gene. Among its several regulatory roles, ... transition of primitive blood-forming cells into white blood cells. ... families who, over generations, have had several relatives with ...
... & Dentistry at the University of Alberta have discovered that ... syndrome in some offspring that could lead to later health ... nuts and red wine, and has been shown to extend ... growing in the womb have an increased risk of developing ...
Cached Biology News:New mutations in leukemia: Researchers found mechanism that can help design future therapies 2New mutations in leukemia: Researchers found mechanism that can help design future therapies 3Gene defect that predisposes people to leukemia discovered 2Gene defect that predisposes people to leukemia discovered 3Powerful antioxidant resveratrol prevents metabolic syndrome in lab tests: U of A study 2
Direct ELISA Assay Diluent, 100 mL...
Direct ELISA Assay Diluent, 10 L...
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
... routine agarose gel electrophoresis into an automated, ... This bufferless, pre-cast system is ideal for ... digests, and more. Fully automated, robot-compatible, and ... 96 system makes your high-throughput screening assignments ...
Biology Products: